Pipeline
| Product Candidate | Indication | Preclinical | Early-Stage Clinical | Late-Stage Clinical |
|---|---|---|---|---|
Nana-val (nanatinostat + valganciclovir) |
Relapsed/Refractory EBV+ Lymphoma | |||
Nana-val |
Recurrent/Metastatic EBV+ Solid Tumors | |||
Other Pre-Clinical |
Undisclosed | |||
| Product Candidate | Indication | Stage |
|---|---|---|
| Nana-val (nanatinostat + valganciclovir) | Relapsed/Refractory EBV+ Lymphoma | Late-Stage Clinical |
| Nana-val | Recurrent/Metastatic EBV+ Solid Tumors | Early-Stage Clinical |
| Other Pre-Clinical | Undisclosed | Preclinical |
Regulatory Status
The U.S. Food and Drug Administration (FDA) has granted Nana-val Fast Track Designation for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoid malignancies, as well as Orphan Drug Designations for the treatment of:
- T-cell lymphoma
- Post-transplant lymphoproliferative disorder (PTLD)
- Plasmablastic lymphoma
- EBV+ diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)
- Nasopharyngeal carcinoma (NPC)
In addition, the European Commission has granted Nana-val Orphan Drug Designation for the treatment of DLBCL and peripheral T-cell lymphoma (PTCL).
Viracta is enrolling patients in clinical trials evaluating Nana-val as a treatment for relapsed/refractory EBV+ lymphomas as well as advanced EBV+ solid tumors. For more information about these studies, see ClinicalTrials.gov. identifiers NCT05011058 and NCT05166577, respectively.
Contact: clinicaltrials@viracta.com
Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.
